EUVIMEDScopri EUVIMED
Multizentrische StudieBeobachtungsstudieOpen access · CC BY-NC 4.0

Patient Reported Outcomes in Primary Sclerosing Cholangitis: An Australian Perspective

Natassia Tan iD, Christopher Zampogna, Kate Lynch, Nicholas Hannah iD, Siddharth Sood, Kate Collins, Avik Majumdar, Andrew Coulshed, Ken Liu iD, Rohit Sawhney, Stephen Bloom, John Lubel and 4 more

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70054 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, 2025. Written by Natassia Tan and 15 co-authors. Institution: Department of Gastroenterology and Hepatology, The Alfred, Melbourne, Australia. Major MEDLINE topics: Cholangitis, Sclerosing, Inflammatory Bowel Diseases, Patient Reported Outcome Measures, Quality of Life. Cited 7 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Dr. Falk Pharma.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background and Aims Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver condition that has a significant association with inflammatory bowel disease (IBD) and impaired health‐related quality of life (HRQOL). We aimed to characterise and compare validated PSC and IBD patient‐reported outcomes (PRO) and determine if PRO correlated with the severity of liver disease.

Methods

We conducted a multicentre, prospective cohort study in Australia enrolling adult patients with PSC from December 2019 to August 2023. Consecutive patients completed a baseline validated PSC PRO questionnaire and a short IBD questionnaire (SIBDQ) if they had concomitant IBD. Linear regression was used to explore factors associated with poor HRQOL and the association between each HRQOL domain and the severity of liver disease.

Results

A total of 55 PSC patients were included. Most patients were male (32/55, 58%) with a median age of 44 years and a median 7 years of follow‐up from PSC diagnosis. Mental and physical fatigue were the most prominent PSC symptoms. All HRQOL domain scores except PSC symptoms were significantly associated with liver disease severity. Decompensated cirrhosis and a history of cholangitis were associated with reduced HRQOL in various domains, whereas older age was protective against emotional distress ( p = 0.01). IBD bowel symptoms and emotional impact had a positive correlation with PSC symptoms and emotional impact within the same patient.

Conclusion

This is the first Australian study describing PSC and IBD PRO in a well‐characterised prospective cohort. We have demonstrated that PSC‐related PRO is significantly associated with liver disease severity. Further large‐scale studies are required to further interrogate these findings.

Subjects

MeSH terms (MEDLINE)

Cholangitis, SclerosingInflammatory Bowel DiseasesPatient Reported Outcome MeasuresQuality of LifeAdultFemaleHumansMaleMiddle AgedAustraliaProspective StudiesSeverity of Illness IndexSurveys and Questionnaires

Author keywords

cholangitiscirrhosisdecompensated cirrhosisfatiguehealth‐related quality of lifeinflammatory bowel diseasepatient‐reported outcomesprimary sclerosing cholangitis

Authors and institutions

  • Department of Gastroenterology and Hepatology, The Alfred, Melbourne, Australia.
  • School of Translational Medicine, Monash University, Melbourne, Australia.
  • Department of Gastroenterology and Hepatology, Eastern Health, Melbourne, Australia.
  • Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia.
  • Department of Gastroenterology and Hepatology, Melbourne Health, Melbourne, Australia.
  • University of Melbourne, Melbourne, Australia.

ORCID profiles: Natassia Tan, Nicholas Hannah, Ken Liu, Stuart Roberts, Amanda J Nicoll

Funding

  • Dr. Falk Pharma

Cite

APA

Tan, N., Zampogna, C., Lynch, K., Hannah, N., Sood, S., Collins, K., Majumdar, A., Coulshed, A., Liu, K., Sawhney, R., Bloom, S., Lubel, J., Kemp, W., Roberts, S., Majeed, A., & Nicoll, A. J. (2025). Patient Reported Outcomes in Primary Sclerosing Cholangitis: An Australian Perspective. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70054

Vancouver

Tan N, Zampogna C, Lynch K, Hannah N, Sood S, Collins K, et al. Patient Reported Outcomes in Primary Sclerosing Cholangitis: An Australian Perspective. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70054

BibTeX
@article{Tan2025,
  author = {Tan, Natassia and Zampogna, Christopher and Lynch, Kate and Hannah, Nicholas and Sood, Siddharth and Collins, Kate and Majumdar, Avik and Coulshed, Andrew and Liu, Ken and Sawhney, Rohit and Bloom, Stephen and Lubel, John and Kemp, William and Roberts, Stuart and Majeed, Ammar and Nicoll, Amanda J},
  title = {Patient Reported Outcomes in Primary Sclerosing Cholangitis: An Australian Perspective},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70054}
}
Start for free →